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ABSTRACT 
 
Type 1 Diabetes Mellitus (T1DM) has become a health problem in many countries. T1DM is the consequence of 
autoimmune destruction process of β cells. There was relationship between vitamin D deficiency with T1DM. The 
destruction process was caused by an imbalance of pro-inflammatory and anti-inflammatory cytokines. One of the 
pro-inflammatory cytokines is IL-2. C-peptide examination to see the function of beta cells due to destruction of 
pancreatic beta cell. Administration of vitamin D3 supplementation still cause controversy and give varying results. 
This randomized clinical trial was conducted to determine the levels of 25(OH)D3, IL-2, and C-peptide in people 
with T1DM who received vitamin D3 supplementation. The subjects were 26 children with T1DM, divided into K1 
group (received vitamin D3 supplementation) and K2 group (received placebo). The results showed higher levels of 
25(OH)D3 in the K1 group and statistically found a significant difference (p = 0.00). Higher levels of IL-2 and lower 
C-peptide were obtained in the K1 group and no statistically significant differences were found (p = 0.76 and p= 
0.26). The insignificant relationship and the negative correlation were found between 25(OH)D3 and IL-2 (p = 0.71; 
r = - 0.12), 25(OH)D3 and C-peptide (p = 0.59; r = -0.16), also levels of IL-2 and C-peptide (p = 0.13; r = -0.44) in 
children with type 1 diabetes who received vitamin D3 supplementation. From this study can be concluded that 
administration vitamin D3 supplementation in patients with T1DM can increase levels 25(OH)D3 significantly. This 
increase has not significantly lowered levels of IL-2 and increased levels of C-peptide. However, there was an absolute 
decrease in the rate of slower C-peptide in the supplemented group than in the placebo group. 
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INTRODUCTION 
Type 1 Diabetes Mellitus (T1DM) has become a 
health problem in many countries, with an overall in-
crease estimation is 3% per year. In 2010, children who 
suffer from T1DM has reach 480,000 patients worldwide 
and the number of new cases which diagnosed each year 
reach 75,800 children [1]. The prevalence of T1DM in 
Indonesia was 3.1 per 100,000 population in 2011 [2]. 
While the number of children with T1DM at Saiful 
Anwar Hospital (RSSA) Malang between the years 2005 
to 2012 was 1.8 per 100,000 population [3]. 
Type 1 Diabetes Mellitus is the consequence of au-
toimmune destruction process of β cells, which produce 
insulin hormone, and the result of interactions between 
multiple genes and environmental exposures [4, 5]. Re- 
cently, researcher has discovered relationship between 
vitamin D deficiency with the risk of chronic diseases, 
including autoimmune diseases such as T1DM. Vitamin 
D3 turns out to has immunosuppressive effect, thus it 
can prevent insulitis and further destruction of pancre-
atic cells [6, 7]. The process of autoimmune destruction 
of β cells occurs due to an imbalance of pro-inflamma-
tory and anti-inflammatory cytokines. One of the pro-
inflammatory cytokines that play a role in T1DM is in-
terleukin-2 (IL-2). IL-2 and IFN-γ will activate cytotoxic 
T cells to destroy target cells presented by the Major 
Histocompatibility Complex (MHC). In addition, this 
cytokine combination will activate the natural killer 
(NK) cell [8]. Autoimmune destruction of pancreatic 
beta cell in T1DM causes the need for an examination 
Levels of 25(OH)D3, IL-2, and C-peptide in Children with T1DM  
  
 
JTLS | J. Trop. Life. Science 29 Volume 8 | Number 1 | January | 2018 
that is sensitive to see the function of β cells. Examina-
tion of C-peptide can be used to assess secretion of en-
dogenous insulin released by the β cells of the pancreas 
[9, 10].  
Research in various countries, such as in the United 
States, Switzerland, Australia, and Indonesia mentioned 
that people with T1DM suffered from vitamin D defi-
ciency and insufficiency [11, 12, 13, 14]. Administration 
vitamin D3 supplementation can prevent or reduce au-
toimmune damage and destruction of pancreatic β cells 
[7]. Many studies were conducted in various countries 
to determine the effect of vitamin D3 supplementation 
on levels of 25(OH)D3, IL-2, and C-peptide in children 
with T1DM. The results obtained are still varied and still 
cause controversy [15, 16]. Current research on the ef-
fect of vitamin D3 supplementation on levels of 
25(OH)D3, IL-2, and C-peptide in children with T1DM 
is not present in Indonesia. Therefore, the purpose of 
this study was to determine the effect of vitamin D3 sup-
plementation on levels of 25(OH)D3, IL-2, and C-pep-
tide in children with T1DM. 
 
MATERIALS AND METHODS 
Study design 
This experimental study was designed as random-
ized clinical trial (RCT) double blind, pre- and post-test 
control group. Vitamin D3 supplementation was admin-
istered for 6 months. Before treatment, subjects with 
T1DM was measured for 25(OH)D3, IL-2, and C-pep-
tide level. Then, all subjects were randomly divided into 
2 groups (K1 and K2) as follow: K1: subjects were 
treated with insulin 0.5-2 IU/day + vitamin D3 2000 
IU/day (D-Vit, PT. Gracia Pharmindo) for 6 months, 
K2: subjects were treated with insulin 0.5-2 IU/day + 
placebo (flour containing capsules, D3 Farmasi. Ltd) for 
6 months. All procedures in this study had been ap-
proved by Ethical Committee of Research, RSSA, Ma-
lang, Indonesia. 
 
Subjects 
As many as 26 subjects were included in this study 
(13 subjects K1 and 13 subjects K2). Subjects were taken 
from Pediatric Endocrinology Outpatient Care, Saiful 
Anwar General Hospital, Malang, Indonesia during 
April-October 2016. Inclusion criteria for subjects are as 
follows: diagnosed as T1DM, age 1-18 years old, not on 
vitamin D3 supplementation, and allowed by his/her 
parents (informed consent). Exclusion criteria for sub-
jects is T1DM patients with other autoimmune disease, 
severe infection, hepatic dysfunction, renal dysfunction,  
anemia and on vitamin D3 supplementation. 
 
Measurement of 25(OH)D3 level 
Based on the manufacturer's instruction (Orgentec, 
Alegria, Germany), this research used Enzyme Linked 
Immunosorbent Assay to assess the level of Vitamin D 
(25(OH)D3). The samples used were plasma stored at -
20°C. The method of inspection is to prepare a polypro-
pylene tube, one for calibrator, control and sample. Con-
jugate enzymes, substrate enzymes, sample buffers and 
specific test controls was included in the kit with 8-well-
microstrips. One patient sample used each strip for a 
single determination. We pipetted sample into well No 
1 and mixed with tracer reagent and the 25-OH vitamin 
D3/D2 obtained from vitamin D binding protein. 25-
OH vitamin D and tracer reagent was coated with buffer 
suspension at well 2. A well-reacted reaction in which 
25-OH vitamin D3/D2 and 25-OH vitamin D tracer re-
agents compete to bind 25-OH vitamin D3/D2 antibod-
ies to form complex 25-OH vitamin D3/D2 and anti-
bodies or 25 -OH vitamin D reagent tracer and antibody 
happened when samples and controls was transferred to 
wells No. 3 and No. 4. Covered the plate with plastic 
and incubated at 18 – 25°C for 2 hours. Washed the 
plate to remove unbound and unspecifically bound mol-
ecules. Subsequently enzyme conjugate binds to the im-
mobilized tracer-antibody complexes was added. Plate is 
closed and wrapped with plastic, incubated at 18 – 25°C 
for 30 minutes. We washed the plate to remove unbound 
enzyme conjugate. Added TMB substrate enzymes to 
well than closed and wrapped the plate in a plastic bag.  
The plate was incubated 18 – 25°C for 30 minutes in 
order to get hydrolyzation and color development dur-
ing incubation. We added Stop Solution to the well to 
stop the reaction. Read at 650 nm using the ELISA 
reader for the intensity of the blue color. Vitamin D level 
> 30 ng/mL was defined as a normal level [17]. 
 
Measurement of C-peptide level 
Based on the manufacturer's instruction (Roche, 
Cobas e, USA), this research used Enzyme Linked Im-
munosorbent Assay to assess the level of C-peptide. This 
assay based on the the quantitative sandwich enzyme 
principle. The examination time is 18 minutes at 37°C. 
Examination of C-peptide levels was performed by tak-
ing 20 µL of plasma samples, controls and calibrators at 
well. During the first stage of incubation of the C-pep-
tide examination, the antigen from the sample formed a 
sandwich complex with biotinylated monoclonal C-pep-
tide-specific antibody and a monoclonal antibody C-
 Tjahyo Suryanto, Harjoedi A Tjahjono, Edi Widjajanto, 2018 
 
 
 JTLS | J. Trop. Life. Science 30 Volume 8 | Number 1 | January | 2018 
peptide-specific antibody labeled with a ruthenium com-
pound. The 100 µL conjugate is mixed in each well for 
5 minutes. Incubation for 30 minutes at room tempera-
ture. In the second stage incubation, streptavidin-coated 
microparticles is added and the complex becomes at-
tached to a solid phase through the interaction of biotin 
and streptavidin. The incubated mixture was removed 
and well washed 3 times using a buffer solution. TMB 
solution is mixed into each well including the empty 
one. Incubation for 15 minutes at room temperature. 
We added 50 µL of the Stop Solution at each well to stop 
the reaction and read at 450 nm using the ELISA reader 
for the absorbance. 
 
Measurement of IL-2 level 
Based on the manufacturer's instruction (Biolegend, 
Legend Max, USA), this research used Enzyme Linked 
Immunosorbent Assay to assess the level of IL-2. All re-
agents are prepared at room temperature. Prepare 500 
µL standard solution of 1,000 pg/mL by diluting 25 µL 
standard stock solution in 475 µL Assay Buffer B. Dilute 
6 times from standard solution 1,000 pg/mL in separate 
tube using Assay Buffer B as diluent. We could see the 
Human IL-2 standard concentrations in the tubes from 
1,000 pg/mL to 15.6 pg/mL, respectively, and Assay 
Buffer B was functioning as a standard zero (0 pg/mL). 
Plate is washed 4 times using 1X Wash Buffer solution 
at least 300 µL at each well and remove remaining 1X 
Wash Buffer solution with filter paper every time wash. 
Assay Buffer B solution was added as much as 50 µL in 
each well which will each contain 50 µL the standard 
solution and samples in the appropriate well. Closed the 
plate and incubated for 2 hours while vibrating. Washed 
the plate with 1× Wash Buffer solution 4 times as above. 
The second incubation phase is carried out after being 
added Human IL-2 antibody solution in each well. This 
process is done at room temperature for 1 hour while 
vibrating. The plate was washed with 1× Wash Buffer 
solution 4 times as above. The third incubation phase is 
carried out after being added Avidin-HRP solution to 
each well. This process is done at room temperature for 
30 minutes while vibrating. The plate was washed with 
1× Wash Buffer solution 5 times as above, for 30 seconds 
to 1 minute for each wash in order to minimize the back-
ground. The next incubation phase is carried out after 
being added Substrate Solution F to each well, incubated 
for 20 min in dark condition and the plate need not be 
closed. The wells should turn into a blue color with in-
tensity that is proportional to its concentration. Stopped 
the process by adding a Stop Solution at each well. We 
could see that the color of the solution changed from 
blue to yellow. We read at 450 nm using the ELISA 
reader for the absorbance. 
 
Statistical analysis 
Statistical test was based on data distribution and 
homogeneity by using Shapiro-Wilk test. Statistical dif-
ferences of 25(OH)D3 level after treatment between 
group was analyzed by independent t-test. For differ-
ences of IL-2 and C-peptide level after treatment be-
tween group were analyzed by Mann-Whitney test. Cor-
relation of 25(OH)D3, IL-2, and C-peptide level were 
analyzed by Spearman correlation test. Data was ana-
lyzed at 95% confidence interval (α = 0.05) using SPSS 
for Windows version 17.0. 
 
RESULTS AND DISCUSSION 
Subject characteristics 
Subject characteristics such as sex, age, duration of 
disease (T1DM), insulin dose, and nutritional status was 
shown in Table 1. Data obtained from Table 1 shows the 
most distribution of sex in the two research groups are 
female. For the duration of illness, both groups were 
found to be approximately equal. Nutritional status in 
both groups found more children with well-nourished 
status. Vitamin D status in both groups found more chil-
dren with abnormal vitamin D status (16/26) than chil-
dren with normal vitamin D status (10/26). Age and in-
sulin dose was listed as mean ± standard deviation dan 
between two groups showed no statistically significant 
difference, which obtained p > 0.05, that is 0.80 and 0.57, 
respectively. 
As many as 26 children with T1DM were subjected 
to study and divided into 2 groups, group 1 consisting 
of T1DM patients receiving vitamin D supplementation 
and group 2 consisting of T1DM patients receiving pla-
cebo. The most distribution of sex in the two research 
groups are female. This is in accordance with previous 
research in which the incidence of T1DM in Indonesia  
with male sex ratio compared to female 45 : 55, besides 
that female has proportion 3 times more than male [18]. 
But contrary to data from the IDF in 2011 that says that 
male more than female as much as 1.5 times. However, 
based on ISPAD data in the same year mentioned that 
gender differences to the incidence of T1DM did not 
occur as a whole worldwide [1]. These differences are 
due to differences in population, race, and number of 
research subjects [19]. 
Nutritional status in both groups found more chil-
dren with well nourished.  This is  consistent  with a re- 
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Table 1.  Subject Characteristics 
Characteristics K1 (n = 13) K2 (n = 13) 
Sex   
Male 6 (6/13) 5 (5/13) 
Female 7 (7/13) 8 (8/13) 
Duration of disease   
≤ 5 years 6 (6/13) 7 (7/13) 
> 5 years 7 (7/13) 6 6/13) 
Nutrional status   
Well nourished 8 (8/13) 11 (11/13) 
Undernourished 5 (5/13) 2 (2/13) 
25(OH)D3 status   
Deficiency 5 (5/13) 5 (5/13) 
Insufficiency 2 (2/13) 4 (4/13) 
Sufficiency  6 (6/13) 4 (4/13) 
Age (years) 12.46 ± 2.99 12.15 ± 3.26 
Insulin dose (IU/kg BW) 1.14 ± 0.16 1.19 ± 0.29 
 
Table 2.  Results of comparison of levels of 25(OH)D3. IL-2, and 
C-peptide in the group receiving vitamin D supple-
mentation compared with the placebo group 
Variable K1 K2 p-value 
25(OH)D3 104.75 ± 39.51 18.56 ± 23.31 0.00 
C-peptide -0.08 ± 0.08 -0.04 ± 0.03 0.26 
IL-2 110.12 ± 378.96 31.58 ± 316.46 0.76 
 
search in Brazil where 59% of T1DM people with well 
nourished, 1% with malnutrition, and 40% with obesity 
[20]. In theory, nutritional status has no direct effect on 
T1DM because decreased insulin secretion that occurs 
due to autoimmune process is not due to decreased in-
sulin sensitivity as occurs in other types of DM [21]. 
Puberty is a transitional period between childhood 
and adulthood that is influenced by complex factors. At 
this time there are physical and psychological changes 
that arise due to changes in endocrine activity sequen-
tially and regularly. In the United States most girls will 
experience puberty at the age of 8 – 13 years, while boys 
are aged 9 – 14 years [22]. Onset, peak work, and dura-
tion of insulin work are the decisive factors in the man-
agement of DM patients. Insulin dose adjustment aims 
to achieve optimal metabolic control, without increasing 
the risk of hypoglycemia and without neglecting the 
quality of life of patients both short and long term. Dur-
ing the ‘honeymoon’ period the total daily dose of insu- 
lin is < 0.5 IU/kgBW/day, the child before puberty (out-
side the ‘honeymoon’ period) in the dose range of 0.7-
1.0 IU/kgBW/day, while during puberty the need in-
creases above 1 IU to 2 IU/kgBW/day [23, 24]. This may 
be the case in this study, with mean age of 12.46 ± 2.99 
years for the K1 group and 12.15 ± 3.26 years for the K2 
group which is the age of puberty, so that an average 
insulin dose of 11.14 ± 0.16 and 1.19 ± 0.29 IU/kgBW/ 
day for each group in order. 
 
Level of 25(OH)D3. IL-2, dan C-peptide in the group re-
ceiving vitamin D supplementation compared with the 
placebo group 
Based on data normality test, it was found that levels 
of 25(OH)D3 in both groups were normally distributed 
(p > 0,05) while the levels of IL-2 and C-peptide were 
not normally distributed (p < 0.05). From different test, 
there was a significant difference in the levels of 
25(OH)D3 among the group receiving vitamin D sup-
plementation and the group receiving placebo (p = 0.00). 
But non-significant differences were found in the levels 
of IL-2 (p = 0.76) and C-peptide (p = 0.26) between two 
groups (Table 2). 
Vitamin D status in the study sample was domi-
nated by abnormal levels of 25(OH)D3, either deficiency 
or insufficiency, with a total of 16 people. This indicates 
that 61.5% of patients with T1DM who are the subjects 
of our study have low levels of 25(OH)D3. Similarly, 
when the subjects were divided into two groups: those 
receiving vitamin D supplementation and placebo, both 
were dominated by low levels of 25(OH)D3, i.e. 7 people 
(54%) and 9 people (69%), respectively. Our research is 
in line with previous research conducted in RSSA Ma-
lang, 90% of children with T1DM had low levels of 
25(OH)D3 [14]. The same result also obtained in various 
countries, such as in the United States, Switzerland, and 
Australia, where in patients with T1DM suffered from 
vitamin D deficiency and insufficiency [11, 12, 13]. 
In this study, higher levels of 25(OH)D3 were ob-
tained in the group with vitamin D supplementation. 
Statistically between the groups receiving vitamin D 
supplementation and the placebo group there was a sig- 
nificant difference (p = 0.00). These results were con-
sistent with a randomized study in which 15 patients 
with T1DM got 1 year of daily oral vitamin D therapy 
(2000 IU), DHA (38 mg/kg) and intensive diabetes 
management found vitamin D levels remained stable in 
patients receiving supplementation but decreased in the 
control group [25]. Another study, 8 patients with 
25(OH)D3 deficiency of 15 patients with T1DM consec-
utively received vitamin D3 supplementation for up to 
one year. Target levels of 25(OH)D3 in the blood are 
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achieved and persist after one year of treatment [26]. 
Study of T1DM patients in Boston was randomized and 
divided into 4 groups with each group given placebo, 
vitamin D3 1,000, 2,000, or 4,000 IU for 3 months. 
Higher levels of vitamin D increased after 3 months with 
the highest levels in the group receiving vitamin D3 4000 
IU [27]. A cross-sectional study of 141 T1DM patients 
and given 1000 IU/day cholecalciferol as supplementa-
tion. There was a significant difference in levels of 
25(OH)D3 between subjects with control and found to 
be a significant increase in levels of 25(OH)D3 [28]. 
 
Correlations among levels of 25(OH)D3. IL-2, and C-
peptide in the group receiving vitamin D supplementa-
tion 
Based on Spearman correlation test, it was found 
that levels of 25(OH)D3 with C-peptide levels, 
25(OH)D3 levels with IL-2 levels, and C-peptide levels 
with IL-2 levels were all not significantly correlated (p = 
0.59; p = 0.71; p = 0.13). It can be concluded that there 
is no significant relationship between these three varia-
bles (Table 3). 
In this study we found lower levels of C-peptide in 
the group with vitamin D supplementation, although 
the absolute level of decreased C-peptide was slower in 
the group receiving supplementation than those receiv-
ing placebo. Cumulative incidence of progression to un-
detectable levels of C-peptide reached 38.5% in the gro-
up receiving vitamin D supplementation and 69.2% in 
the placebo group. Statistically no significant differences 
in C-peptide levels were obtained between groups re-
ceiving vitamin D supplementation with the group re-
ceiving placebo (p = 0.26). This is consistent with studies 
conducting a case-control intervention study in 30 chil-
dren with T1DM. After administering oral doses of cho-
lecalciferol 2000 IU/day for 6 months, the decreased ten-
dency was lower than the β-cell function seen. The per-
centage reduction of C-peptide was also lower in the in-
tervention group compared with the control group. 
Three (20%) patients in the control group progressed to 
an undetectable C-peptide during the study period com-
pared to 1 (6%) in the intervention group [29]. In an-
other study 38 patients with T1DM were randomly as-
signed either daily oral therapy of cholecalciferol 2000 
IU, or placebo. The cumulative incidence of progression 
to undetectable fasting C-peptide level reached 18.7% in 
the cholecalciferol group and 62.5% in the placebo 
group. Therefore, cholecalciferol is safely used as an ad-
junctive therapy with insulin and is associated with pro-
tective immunological effects and a slow decline in the 
function of residual β -cells in patients with T1DM [30]. 
A study of patients aged 18 – 39 years in Germany who 
was newly diagnosed with T1DM who received 0.25 µg 
1.25(OH)2D3 or placebo daily for 9 months and followed 
for a total of 18 months. The results obtained no differ-
ences in the area under curve (AUC) C-peptide, peak C-
peptide, and fast C-peptide between the treated group 
and placebo [31]. In another study, 34 patients were 
newly diagnosed with T1DM in a double-blind trial with 
calcitriol 0.25 µg/day or placebo and followed for 2 
years. The levels of C-peptide fell significantly, but in 
both groups had similar levels, with no significant dif-
ference [32].  
Different results were obtained in studies in China, 
where plasma C-peptide, fasting C-peptide (FCP) and 
postprandial C-peptide (PCP) levels, remained stable in 
the insulin-assisted group plus 1-alpha(OH)D3, while 
FCP levels decreased in the insulin-only group during 
the 12-month intervention. Seventy percent of patients 
treated with 1-alpha(OH)D3 of their FCP concentra-
tions persisted or increased after 1 year of treatment, 
while only 22% of the patients treated with insulin alone 
had stable FCP levels. Further analysis with different 
time periods of diabetes showed that better beta-cell beta 
functions were maintained (reflected significantly higher 
FCP and PCP levels) in the group receiving 1-al-
pha(OH)D3 therapy plus Insulin [33]. Research in Iran, 
where the intervention group received alfacalcidol 0.25 
µg twice daily, while the control group received placebo. 
There was a higher FCP result and lower daily insulin 
dosage per body weight (DID) in the intervention 
group, with males having a stronger response to alfacal-
cidol. No side effects were observed [34]. Another study, 
8 patients with 25(OH)D3 deficiency, of 15 patients with 
T1DM consecutively received vitamin D3 supplementa-
tion for up to one year. Target levels of 25(OH)D3 in 
blood were achieved and persisted after one year of treat- 
 
Table 3.  Results of correlation between levels of 25(OH)D3. IL-
2, and C-peptide in the group receiving vitamin D sup-
plementation  
Variable p-value r-value 
Level of 25(OH)D3 
with level of C-peptide 
0.59 - 0.164 
Level of 25(OH)D3 
with level of IL-2 
0.71 - 0.115 
Level of C-peptide with 
level of IL-2 
0.13 - 0.441 
Levels of 25(OH)D3, IL-2, and C-peptide in Children with T1DM  
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ment and the C-peptide value remained stable after one 
year of treatment [26]. 
In this study, higher levels of IL-2 were found in the 
group receiving vitamin D supplementation. Statistically 
between the groups receiving vitamin D supplementa-
tion and the placebo group did not differ significantly 
(p= 0.76). Some studies reported direct modulation of 
CD4 + T cells with active vitamin D, and Treg cell in-
duction expressed IL-17, IL-21, IFN-γ CTLA-4 and 
FoxP3 inhibition. If T cells grow in an environment rich 
in IL-2 and vitamin D, they express the highest levels of 
CTLA-4 and FoxP3, and are capable of suppressing CD4 
+ T cell proliferation [35,36]. But in his latest study, 
1.25(OH)2D3 did not significantly affect the overall ex-
pression of FoxP3 or IL-2 but that changed the magni-
tude of the cytokine effect. Nevertheless, the presence or 
absence of 1.25(OH)2D3 inflammatory cytokines re-
duced the effects of TGFβ on the increase of FoxP3 and 
IL-2 [37].  
There was no significant association between levels 
of 25(OH)D3 and C-peptide levels in children with 
T1DM who received vitamin D supplementation, with 
very weak association and negative correlation (p = 0.59; 
r = -0.16). Research in Germany and Italy also obtained 
similar results [31, 32]. This is due to the duration of 
disease in this study subjects averaged still a decade so 
obtained low levels of C-peptide despite the increase of 
25(OH)D3 and this indicates that the progressive de-
struction of pancreatic β cells occur mainly in the first 
years of the emergence T1DM disease [38]. In addition, 
the onset that occurs at a young age also affects the levels 
of C-peptide [39]. This result is different from the stud-
ies conducted in China where there was a significant 
positive correlation between vitamin D levels and C-
peptide levels [33]. Similarly, the results of a study con-
ducted in Boston showed a significant positive correla-
tion between vitamin D and C-peptide levels [27]. 
There was no significant association between levels 
of 25(OH)D3 and IL-2 levels in children with T1DM 
who received vitamin D supplementation, with very 
weak association and negative correlation (p = 0.71; r= - 
0.12). Overbergh et al, showed that in NOD rats the 
shift between Th1 / Th2 cells also occurs in the periph-
ery and is not limited to the pancreas. Furthermore, this 
change only occurs in immune responses with specific 
autoantigen (GAD65 exposure, B-chain insulin, heat 
shock protein 65), and not observed in the immune re-
sponse associated with other antigens (ovalbumin, teta-
nus toxin, and others). Vitamin 1.25(OH)2D3 clearly 
causes a decrease in IL-12 and 2 tested Th1 cytokines 
(IFN-γ and IL-2) after administration of GAD65. De-
creased expression of IL-12 is not surprising since 
1.25(OH)2D3 can directly inhibit IL-12 transcription. 
Because of the central role of IL-12 as the main stimu-
lant for Th1 cytokine, decreased expression of IL-12, as 
expected, is accompanied by similar reductions in IFN- 
and IL-2 [40]. In another study of IL-2 effect mecha-
nisms showed that in the absence of these cytokines, 
Treg cells could not survive or expand their numbers in 
the thymus and peripheral parts [41] and were unable 
to suppress T cell [42]. From these data, it can be con-
cluded that IL-2 has an important and not excessive 
function in development, homeostasis, and Treg cell 
function [43]. This is not in line with studies reporting 
direct modulation of CD4+ T cells with active vitamin 
D, and Treg cell induction expressed IL-17, IL-21, IFN-
γ CTLA-4 and FoxP3 inhibition. If T cells grow in an 
environment rich in IL-2 and vitamin D, they express 
the highest levels of CTLA-4 and FoxP3, and are able to 
suppress CD4+ T cell proliferation [35,36].  
There was no significant association between IL-2 
and C-peptide levels in children with T1DM who re-
ceived vitamin D supplementation, with moderate cor-
relation and negative correlation (p = 0.13; r = -0.44). 
From the research conducted by Dragovic et al., ob-
tained a negative correlation after vitamin D supplemen-
tation between IL-2 and C-peptide. This is indicated by 
a decrease in the incidence of chronic complications of 
T1DM and an improvement in the complications result-
ing from increased C-peptide and IL-2 reduction [44]. 
The same thing is also shown by research in California, 
which is obtained a negative correlation between C-pep-
tide and IL-2 [45]. 
Limitations in our study are limited samples just in 
Malang, so it is less able to describe the status of vitamin 
D in patients with T1DM in Indonesia. Difficult factors 
that may arise in this study also cannot be controlled as 
ideal as possible, such as low vitamin D dietary factors, 
sun exposure, ethnicity/race, body surface area, and 
drugs that may affect vitamin D status research subjects 
who may be contributing to the occurrence of vitamin 
D deficiency are not examined in this study. Other fac-
tors that can affect the levels of C-peptide and IL-2. In 
addition, there are other factors that may affect the re-
sults of research but have not been studied, among oth-
ers, IL-17, IL-10, IL-12, TGF-β, IFN-γ, and VDR. It is 
desirable to do further research with more homogeneous 
sampling by further tightening the inclusion criteria in 
order to obtain better and meaningful results. 
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CONCLUSION 
From this study can be concluded that administra-
tion vitamin D3 supplementation in patients with T1DM 
can increase levels 25(OH)D3 significantly. This increase 
has not significantly lowered levels of IL-2 and increased 
levels of C-peptide. However, there was an absolute de-
crease in the rate of slower C-peptide in the supple-
mented group than in the placebo group. 
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